

Hiroaki Tanaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3508133/publications.pdf>

Version: 2024-02-01

11
papers

41
citations

2258059

3
h-index

1872680

6
g-index

12
all docs

12
docs citations

12
times ranked

60
citing authors

#	ARTICLE	IF	CITATIONS
1	A Pharmacist's Query Avoiding Exacerbation of Adverse Effects in a Patient with Acyclovir Encephalopathy: A Case Report. <i>Yakugaku Zasshi</i> , 2022, 142, 771-774.	0.2	1
2	Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 223-226.	1.5	4
3	Relationship between Epidermal Growth Factor Receptor Mutations and Adverse Events in Non-Small Cell Lung Cancer Patients treated with Afatinib. <i>Journal of Medical Investigation</i> , 2021, 68, 125-128.	0.5	1
4	A puerperal patient with agranulocytosis during tazobactam/piperacillin administration...A case report. <i>Journal of Medical Investigation</i> , 2021, 68, 368-371.	0.5	2
5	Relationship between epidermal growth factor receptor mutations and skin rash in non-small cell lung cancer patients. <i>Journal of Chemotherapy</i> , 2020, 32, 83-87.	1.5	1
6	Study of Usefulness of Automatic Restocking and Dispensing Machine. <i>Iryo Yakugaku (Japanese Journal)</i> Tj ETQq0 0 0 rgBT /Overlock 10	0.1	0
7	Effect of De-escalation Facilitated by Antimicrobial Stewardship Activities on Blood Culture Positive Patient Outcomes. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2020, 46, 314-322.	0.1	1
8	Exploring the Cause and the Preventive Measures of Feeding Tube Occlusion during the Administration of ENSURE LIQUID [®] . <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical)</i> Tj ETQq0 0 0 rgBT /Overlock 10	0.1	0
9	Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 644-648.	1.4	15
10	Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes. <i>Molecular and Clinical Oncology</i> , 2016, 4, 947-953.	1.0	5
11	Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. <i>Molecular and Clinical Oncology</i> , 2013, 1, 225-230.	1.0	9